Celyad Oncology S.A.
Market Cap
$4.83M
P/E Ratio
-0.12
EPS
$-1.44
Dividend Yield
0.00%
52-Week Range
$0.17 — $1.23
Volume
854
Avg Volume
1.10K
Beta
—
Get alerted when 0QFK.L hits your target price.
Free — enter your email to get started
P/E (TTM)
-0.12
Forward P/E
—
PEG Ratio
-0.13
P/S (TTM)
76.05
P/B (TTM)
-4.22
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
0.67%
ROA (TTM)
-1.14%
ROIC
—
Gross Margin
-1.34%
Operating Margin
-35.97%
Net Margin
—
Debt/Equity
-0.27
Current Ratio
0.66
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
+0.44%
EPS Growth (5Y)
+0.28%
Sales Growth (3Y)
+0.27%
Sales Growth (5Y)
-0.07%
EPS Est (This Year)
—
EPS Est (Next Year)
—
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$0.02
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
27.62M
Float
25.95M
Free Float %
93.95%
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Country
BE
Exchange
LSE
IPO Date
2014-01-08
Employees
17
CEO
Matthew R. Kane
Index Membership
—
Website
https://www.celyad.com
Celyad Oncology S.A. (0QFK.L) is a healthcare company in the medical - pharmaceuticals industry listed on the LSE. With a market capitalization of $4.83M, a P/E ratio of -0.12, 0QFK.L is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare 0QFK.L against other stocks using dozens of fundamental and technical filters.
MSLE
Satellos Bioscience Inc. Common Stock
$7.95
+9.35%
$10.24M
AZNH
AstraZeneca PLC ADRhedged
$53.74
+0.03%
$1.60M
AIXC
AIxCrypto Holdings, Inc.
$1.46
+4.35%
$7.53M
BGMS
Bio Green Med Solution, Inc.
$0.97
+4.24%
$2.13M
NVOH
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged
$23.18
+4.12%
$2.08M
HKPD
Cellyan Biotechnology Co., Ltd
$0.63
-6.72%
$6.86M
Celyad Oncology S.A. (0QFK.L) has a trailing twelve-month (TTM) P/E ratio of -0.12. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Celyad Oncology S.A. (0QFK.L) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Celyad Oncology S.A. (0QFK.L) has a market capitalization of $4.83 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.